![]()
- Late Payments on Credit Cards Drop in Third Quarter
- US Job Losses to Bottom out Next Quarter: NABE
- Kraft Weighs Higher Cadbury Bid as Rivals Circle
- MBS Program Should be Extended: Fed's Bullard
- Wall Street Finds Profits by Reducing Mortgages
- Microsoft, News Corp Weigh Online News Pact
- Warren Buffett, Bill Gates 'Walk & Talk' At Columbia
- 10 Tips to Get Out of Debt
- Thanksgiving Week Stuffed With Economic News
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- U.S. Stocks Slip, Dollar Rises
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- iPhone a Better Gaming Platform Than Android?
- May Day For Dendreon
- 100% Mortgage Financing From USDA
NEW YORK, Nov 2 (Reuters) - Patients and doctors should be aware of possible kidney function problems with Eli Lilly and Amylin Pharmaceuticals' Byetta diabetes drug, U.S. health regulators said on Monday. The U.S. Food and Drug Administration received 78 reports of problems with kidney function in patients using Byetta from April 2005 through October 2008. Nearly 7 million prescriptions for the drug were written during roughly the same period, so the agency noted the number of kidney problems represented a "small percentage" of the total number of patients on the drug. Nonetheless, the FDA approved changes to Byetta's prescribing label to include information about the kidney function reports. "Health care professionals and patients taking Byetta should pay close attention to any signs or symptoms of kidney problems," said Amy Egan, an FDA official in the agency's division of metabolism and endocrinology products. (Reporting by Lewis Krauskopf; Editing by Tim Dobbyn) Keywords: FDA/LILLY AMYLIN (lewis.krauskopf@thomsonreuters.com; 646-223-6082;Reuters Messaging:Lewis.Krauskopf.reuters.com@reuters.net;) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved.
The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
- Technology can make or break a fortune in the world of alternative energy.
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- Many people are facing the holidays with substantially smaller incomes. Here’s how some are adapting.
- Jim Cramer is a proponent of stocks that pay healthy dividends, and here are his top five dividend plays.
- The homebuyer's tax credit jacked sales for a while, but 2010 is looking weak. Now what?
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.











